Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics, for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors. Grid is an oncology-focused biotech company building on the science first developed by Edward F. Patz, Jr. MD, and his team of scientists at Duke University Medical Center.
Under the agreement, Catalent Biologics will employ its proprietary GPEx cell line technology to develop cell lines and manufacture antibodies with a view to optimizing the process for cGMP bulk drug production. The project will be undertaken at Catalent’s Madison, Wisconsin, biomanufacturing facility.
Grid’s research is based upon a novel approach to identify specific tumor immunoglobulin G (IgG) antibodies from patients with early stage cancer.
“Grid Therapeutics is excited to partner with Catalent to develop this novel, human-derived antibody for the treatment of cancer. We feel Catalent Biologics is well positioned to bring this novel antibody to the clinic,” said Edward F. Patz, Jr. M.D., CEO of Grid Therapeutics.